Showing results (71-80 of 79) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society|April 30, 2021
Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivorsBerbel L M Ykema, Lisanne S Rigter, Manon C W Spaander, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 27, 2022
Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic RadiotherapyBerbel L M Ykema, Andrea Gini, Lisanne S Rigter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin LymphomaMargaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.Journal of the National Cancer Institute|December 22, 2020
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma PatientsSimone de Vries, Michael Schaapveld, Cécile P M Janus, et al.BMC Cancer|February 9, 2017
Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study designLisanne S Rigter, Manon C W Spaander, Leon M Moons, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patientsRoberto N Miranda, Tariq N Aladily, H Miles Prince, et al.Journal of the National Cancer Institute|March 25, 2026
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphomaYvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, et al.Nature Communications|December 23, 2021
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinomaJoris L Vos, Joris B W Elbers, Oscar Krijgsman, et al.Nature Medicine|October 8, 2025
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trialSabine E Breukers, Joleen J H Traets, Stan W van Dijk, et al.Pageof 8